Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Livzon Mabpharm to Develop Epirus Biosimilars in China

publication date: Sep 25, 2014
China's Livzon Mabpharm will collaborate with Epirus Biopharma of Boston to develop up to five biosimilar drugs for the China market. The first product is a Remicade biosimilar, which was recently approved in India. Livzon will develop the drug for China and Taiwan using Epirus' Scale™ manufacturing platform to produce the drug for these two markets. Livzon was a principal investor in Epirus' $36 million funding in April 2014. More details....

Stock Symbol: (NSDQ: EPRS)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital